Abstract
Current strategies for hepatic gene therapy are either quantitatively inefficient or suffer from lack of permanent gene expression. We have utilized an animal model of hereditary tyrosinaemia type I (HT1), a recessive liver disease caused by deficiency of fumarylacetoacetate hydrolase (FAH), to determine whether in vivo selection of corrected hepatocytes could improve the efficiency of liver gene transfer. As few as 1,000 transplanted wild-type hepatocytes were able to repopulate mutant liver, demonstrating their strong competitive growth advantage. Mutant hepatocytes corrected in situ by retroviral gene transfer were also positively selected. In mutant animals treated by multiple retrovirus injections >90% of hepatocytes became FAH positive and liver function was restored to normal. Our results demonstrate that in vivo selection is a useful strategy for hepatic gene therapy and may lead to effective treatment of human HT1 by retroviral gene transfer
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arias, I.M. The Liver — Biology and Pathobiology (Raven Press, New York, 1994).
Scriver, C.R., Beaudet, A.L., Sly, W. & Valle, D. The Metabolic Basis of Inherited Disease (MacGraw-Hill, NewYork 1994).
Norwich, A.L. Inherited hepatic enzyme defects as candidates for liver-directed gene therapy. Curr. Topics Microbiol. Immun. 168, 185–200 (1991).
Grossman, M. & Wilson, J.M. Retroviruses: delivery vehicle to the liver. Curr. Opin. Genet Dev. 3, 110–114 (1993).
Li, Q., Kay, M.A., Finegold, M., Stratford-Perricaudet, L.D. & Woo, S.L. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 4, 403–409 (1993).
Yang, Y. et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91, 4407–4411 (1994).
Lindblad, B., Lindstedt, S. & Steen, G. On the enzymic defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. USA 74, 4641–4645 (1977).
Mitchell, G.A., Lambert, M. & Tanguay, R.M. in The Metabolic Basis of Inherited Disease. (eds Scriver, C.R., Beaudet, A.L., Sly, W. & Valle, D.) 1077–1106 (MacGraw-Hill, New York, 1994).
Grompe, M. et al. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev. 7, 2298–2307 (1993).
Klebig, M.L., Russell, L.B. & Rinchik, E.M. Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr–1) locus. Proc. Natl. Acad. Sci. USA 89, 1363–1367 (1992).
Ruppert, S. et al. Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice. Genes Dev. 6, 1430–1443 (1992).
Gluecksohn-Waelsch, S. Genetic control of morphogenetic and biochemical differentiation: lethal albino deletions in the mouse. Cell. 16, 225–237 (1979).
Ruppert, S. et al. Two genetically defined trans-acting loci coordinately regulate overlapping sets of liver-specific genes. Cell 61, 895–904 (1990).
Lindstedt, S., Holme, E., Lock, E.A., Hjalmarson, O. & Strandvik, B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340, 813–817 (1992).
Grompe, M. et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nature Genet. 10, 453–460 (1995).
Bain, M.D. et al. Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinemia type I. Eur. J. Pediatr. 149, 637–639 (1990).
Paradis, K. et al. Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am. J. Hum. Genet. 47, 338–342 (1990).
Kvittingen, E.A., Rootwelt, H., Brandtzaeg, P., Bergan, A. & Berger, R. Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. J. Clin. Invest. 91, 1816–1821 (1993).
Kvittingen, E.A., Rootwelt, H., Berger, R. & Brandtzaeg, R. Self-induced correction of the genetic defect in tyrosinemia type I. J. Clin. Invest. 94, 1657–1661 (1994).
Sandgren, E.P. et al. Complete hepatic regeneration after somatic deletion of an alburnin-plasminogen activator transgene. Cell 66, 245–256 (1991).
Rhim, J.A., Sandgren, E.R., Degen, J.L. & Brinster, R.L. Replacement of disease mouse liver by hepatic cell transplantation. Science 263, 1149–1152 (1994).
Rhim, J.A., Sandgren, E.R., Palmiter, R.D. & Brinster, R.L. Complete reconstitution of mouse liver with xenogeneic hepatocytes. Proc. Natl. Acad. Sci. USA 92, 4942–4946 (1995).
Kay, M.A. et al. Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc. Natl. Acad. Sci. USA 89, 89–93 (1992).
Grossman, M. et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia. Nature Genet. 6, 335–341 (1994).
Chowdhury, J.R. et al. Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science. 254, 1802–1805 (1991).
Kay, M.A. et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 262, 117–119 (1993).
Hirschhorn, R., Yang, D.R., Israni, A., Huie, M.L. & Ownby, D.R. Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery. Am. J. Hum. Genet. 56, 59–68 (1994).
Russo, P. & O'Regan, S. Visceral pathology of hereditary tyrosinemia type I Am. J. Hum. Genet. 47, 317–324 (1990).
Gerber, M.A. & Thung, S.N. in The role of cell types in hepatocarcinogenesis. (ed. Sirica, A.E.) 209–226 (CRC Press, Boca Raton, 1992).
Fausto, N., In The Liver — Biology and Pathobiology. (ed. Arias, I.M.) 1501–1518 (Raven Press, New York, 1994).
Becker, A.F., McCulloch, E.A. & Till, J.E. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 197, 452–455 (1963).
Lemischka, I.R., Raulet, D.H. & Mulligan, R.C. Developmental potential and dynamic behavior of hematopoietic stem cells. Cell 45, 917–927 (1986).
Cepko, C.L., Ryder, E.F., Austin, C.R., Walsh, C. & Fekete, D.M. Lineage analysis using retrovirus vectors. Mefn. Enzym. 225, 933–960 (1993).
Grompe, M., Jones, S.N., Loulseged, H. & Caskey, C.T. Retroviral-mediated gene transfer of human ornithine transcarbamylase into primary hepatocytes of spf and spf-ash mice. Hum. Gene Ther. 3, 35–44 (1992).
Ponder, K.R. et al. Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. Proc. Natl. Acad. Sci. USA 88, 1217–1221 (1991).
Phaneuf, D. et al. Cloning and expression of the cDNA encoding human fumarylacetoacetae hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15. Am. J. Hum. Genet. 48, 525–535 (1991).
McLachlin, J.R., Mittereder, N., Daucher, M.B., Kadan, M. & Eglitis, M.A. Factors affecting retroviral vector function and structural integrity. Virology 195, 1–5 (1993).
Markowitz, D., Goff, S. & Bank, A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62, 1120–1124 (1988).
Markowitz, D., Goff, S. & Bank, A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167, 400–406 (1988).
Vrancken Peeters, M.J., Lieber, A., Perkins, J. & Kay, M.A. Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques (in the press).
Miller, S.A., Dykes, D.D. & Polesky, H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl. Acids Res. 16, 1215 (1988).
Chomczynski, P. & Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156–159 (1987).
Sambrook, J., Fritsch, E.R. & Maniatis, T., Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989).
Gubbay, J. et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature 346, 245–250 (1990).
Davis, R.L., Weintraub, H. & Lassar, A.B. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51, 987–1000 (1987).
Grompe, M. & al-Dhalimy, M. Nucleotide sequence of a cDNA encoding murine fumarylacetoacetate hydrolase. Biochem. Med. Metab. Biol. 48, 26–31 (1992).
Grenier, A. & Lescault, A., Methods of Enzymatic Analysis. (ed. Bergmeyer, H.) 79 (VCH Verlagsgesellschaft, Weinheim, F.R. Germany, 1985).
Knox, W.E. & Edwards, S.W. Enzymes involved in conversion of tyrosine to acetoacetate. Meth. Enzym. 2, 287–300 (1955).
Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.Anal. Biochem. 72, 248–254 (1976).
Tanguay, R.M. et al. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am. J. Hum. Genet. 47, 308–316 (1990).
Labelle, Y.,, Puymirat, J. & Tanguay, R.M. Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1. Biochim. Biophys. Acta. 1180, 250–256 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Overturf, K., Al-Dhalimy, M., Tanguay, R. et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet 12, 266–273 (1996). https://doi.org/10.1038/ng0396-266
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ng0396-266
This article is cited by
-
Acute liver steatosis translationally controls the epigenetic regulator MIER1 to promote liver regeneration in a study with male mice
Nature Communications (2023)
-
IL6 supports long-term expansion of hepatocytes in vitro
Nature Communications (2022)
-
Generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver
Cell & Bioscience (2022)
-
A versatile transposon-based technology to generate loss- and gain-of-function phenotypes in the mouse liver
BMC Biology (2022)
-
Proliferative polyploid cells give rise to tumors via ploidy reduction
Nature Communications (2021)